Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): PMS-Clobetasol (02309521), PMS-Clobetasol (02309548), Teva-Clobetasol (01910299). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Clobetasol propionate
Form:
20 of 20 products shown
11 general benefit · 9 not a benefit
Dermovate · DIN 02213265 · 0.05% · Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Dermovate · DIN 02213265
Manufacturer: TaroPharma, a Division of Taro Pharmaceuticals Inc.; listing date 1998-05-21
Health Canada: Marketed since 2004-03-29 · brand DERMOVATE CREAM · ATC D07AD01 CLOBETASOL · form Cream · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
DIN 02213265: Dermovate
Raw flags: sec3=Y
Item: 840600061; group id 841; item number 2046; lccId None; manufacturer id TPH
Source form: Cr; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $1.0203; ministry $0.2279
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213265
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36952Interchangeable products
Mylan-Clobetasol · DIN 02024187 · $0.2279
Taro-Clobetasol Cream USP · DIN 02245523 · $0.2279
Teva-Clobetasol · DIN 01910272 · $0.2279
Shortage status: resolved shortage (ended September 8, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213265
Shortage record checked October 6, 2026
Mylan-Clobetasol · DIN 02024187 · 0.05% · Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Clobetasol · DIN 02024187
Manufacturer: Mylan Pharmaceuticals ULC; listing date 1996-10-01
Health Canada: Marketed since 2010-07-21 · brand MYLAN-CLOBETASOL CREAM · ATC D07AD01 CLOBETASOL · form Cream · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Clobetasol: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2279). What the ministry pays, not the patient.
DIN 02024187: Mylan-Clobetasol
Raw flags: sec3=Y
Item: 840600061; group id 841; item number 2046; lccId None; manufacturer id MYL
Source form: Cr; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.2279; ministry $0.2279
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02024187
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14381Interchangeable products
Dermovate · DIN 02213265 · $0.2279
Taro-Clobetasol Cream USP · DIN 02245523 · $0.2279
Teva-Clobetasol · DIN 01910272 · $0.2279
Shortage status: resolved shortage (ended November 7, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02024187
Shortage record checked October 6, 2026
Taro-Clobetasol Cream USP · DIN 02245523 · 0.05% · Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Clobetasol Cream USP · DIN 02245523
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2003-01-30
Health Canada: Marketed since 2005-10-03 · brand TARO-CLOBETASOL CREAM USP, 0.05% · ATC D07AD01 CLOBETASOL · form Cream · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Taro pharmaceuticals inc · schedule Prescription
Taro-Clobetasol Cream USP: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2279). What the ministry pays, not the patient.
DIN 02245523: Taro-Clobetasol Cream USP
Raw flags: sec3=Y
Item: 840600061; group id 841; item number 2046; lccId None; manufacturer id TAR
Source form: Cr; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.2279; ministry $0.2279
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245523
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69610Interchangeable products
Dermovate · DIN 02213265 · $0.2279
Mylan-Clobetasol · DIN 02024187 · $0.2279
Teva-Clobetasol · DIN 01910272 · $0.2279
Shortage status: discontinued (May 19, 2026, reported by TARO PHARMACEUTICALS INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245523
Shortage record checked October 6, 2026
Teva-Clobetasol · DIN 01910272 · 0.05% · Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Clobetasol · DIN 01910272
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2017-12-19 · brand TEVA-CLOBETASOL · ATC D07AD01 CLOBETASOL · form Cream · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Teva canada limited · schedule Prescription
Teva-Clobetasol: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2279). What the ministry pays, not the patient.
DIN 01910272: Teva-Clobetasol
Raw flags: sec3=Y
Item: 840600061; group id 841; item number 2046; lccId None; manufacturer id TEV
Source form: Cr; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.2279; ministry $0.2279
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01910272
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13437Interchangeable products
Dermovate · DIN 02213265 · $0.2279
Mylan-Clobetasol · DIN 02024187 · $0.2279
Taro-Clobetasol Cream USP · DIN 02245523 · $0.2279
Shortage status: resolved shortage (ended April 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01910272
Shortage record checked October 6, 2026
Dermovate · DIN 02213273 · 0.05% · Oint
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Dermovate · DIN 02213273
Manufacturer: TaroPharma, a Division of Taro Pharmaceuticals Inc.; listing date 1998-05-02
Health Canada: Marketed since 2004-04-06 · brand DERMOVATE OINTMENT · ATC D07AD01 CLOBETASOL · form Ointment · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
DIN 02213273: Dermovate
Raw flags: sec3=Y
Item: 840600062; group id 841; item number 2047; lccId None; manufacturer id TPH
Source form: Oint; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $1.0203; ministry $0.2279
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213273
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36953Interchangeable products
Mylan-Clobetasol · DIN 02026767 · $0.2279
Taro-Clobetasol Ointment USP · DIN 02245524 · $0.2279
Teva-Clobetasol · DIN 01910280 · $0.2279
Shortage status: resolved shortage (ended March 25, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213273
Shortage record checked October 6, 2026
Mylan-Clobetasol · DIN 02026767 · 0.05% · Oint
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Clobetasol · DIN 02026767
Manufacturer: Mylan Pharmaceuticals ULC; listing date 1996-10-01
Health Canada: Marketed since 2010-08-31 · brand MYLAN-CLOBETASOL OINTMENT · ATC D07AD01 CLOBETASOL · form Ointment · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Clobetasol: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2279). What the ministry pays, not the patient.
DIN 02026767: Mylan-Clobetasol
Raw flags: sec3=Y
Item: 840600062; group id 841; item number 2047; lccId None; manufacturer id MYL
Source form: Oint; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.2279; ministry $0.2279
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02026767
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14382Interchangeable products
Dermovate · DIN 02213273 · $0.2279
Taro-Clobetasol Ointment USP · DIN 02245524 · $0.2279
Teva-Clobetasol · DIN 01910280 · $0.2279
Shortage status: resolved shortage (ended October 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02026767
Shortage record checked October 6, 2026
Taro-Clobetasol Ointment USP · DIN 02245524 · 0.05% · Oint
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Clobetasol Ointment USP · DIN 02245524
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2003-01-30
Health Canada: Marketed since 2005-10-03 · brand TARO-CLOBETASOL OINTMENT USP, 0.05% · ATC D07AD01 CLOBETASOL · form Ointment · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Taro pharmaceuticals inc · schedule Prescription
Taro-Clobetasol Ointment USP: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2279). What the ministry pays, not the patient.
DIN 02245524: Taro-Clobetasol Ointment USP
Raw flags: sec3=Y
Item: 840600062; group id 841; item number 2047; lccId None; manufacturer id TAR
Source form: Oint; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.2279; ministry $0.2279
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245524
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69611Interchangeable products
Dermovate · DIN 02213273 · $0.2279
Mylan-Clobetasol · DIN 02026767 · $0.2279
Teva-Clobetasol · DIN 01910280 · $0.2279
Shortage status: discontinued (January 25, 2026, reported by TARO PHARMACEUTICALS INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245524
Shortage record checked October 6, 2026
Teva-Clobetasol · DIN 01910280 · 0.05% · Oint
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Clobetasol · DIN 01910280
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2017-12-19 · brand TEVA-CLOBETASOL · ATC D07AD01 CLOBETASOL · form Ointment · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Teva canada limited · schedule Prescription
Teva-Clobetasol: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2279). What the ministry pays, not the patient.
DIN 01910280: Teva-Clobetasol
Raw flags: sec3=Y
Item: 840600062; group id 841; item number 2047; lccId None; manufacturer id TEV
Source form: Oint; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.2279; ministry $0.2279
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01910280
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13439Interchangeable products
Dermovate · DIN 02213273 · $0.2279
Mylan-Clobetasol · DIN 02026767 · $0.2279
Taro-Clobetasol Ointment USP · DIN 02245524 · $0.2279
Shortage status: resolved shortage (ended November 14, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01910280
Shortage record checked October 6, 2026
Dermovate · DIN 02213281 · 0.05% · Scalp Lot
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Dermovate · DIN 02213281
Manufacturer: TaroPharma, a Division of Taro Pharmaceuticals Inc.; listing date 2003-01-30
Health Canada: Marketed since 2004-04-23 · brand DERMOVATE SCALP APPLICATION · ATC D07AD01 CLOBETASOL · form Solution · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
DIN 02213281: Dermovate
Raw flags: sec3=Y
Item: 840600070; group id 841; item number 2048; lccId None; manufacturer id TPH
Source form: Scalp Lot; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.8184; ministry $0.3996
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213281
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36954Interchangeable products
Mylan-Clobetasol Scalp Application · DIN 02216213 · $0.3996
Taro-Clobetasol Topical Solution USP · DIN 02245522 · $0.3996
Shortage status: resolved shortage (ended January 31, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213281
Shortage record checked October 6, 2026
Mylan-Clobetasol Scalp Application · DIN 02216213 · 0.05% · Scalp Lot
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Clobetasol Scalp Application · DIN 02216213
Manufacturer: Mylan Pharmaceuticals ULC; listing date 1996-10-01
Health Canada: Marketed since 2010-03-02 · brand MYLAN-CLOBETASOL SCALP APPLICATION · ATC D07AD01 CLOBETASOL · form Lotion · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Clobetasol Scalp Application: Formulary list price $0.40 per unit (the source does not state the unit; exact figure $0.3996). What the ministry pays, not the patient.
DIN 02216213: Mylan-Clobetasol Scalp Application
Raw flags: sec3=Y
Item: 840600070; group id 841; item number 2048; lccId None; manufacturer id MYL
Source form: Scalp Lot; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.3996; ministry $0.3996
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02216213
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43175Interchangeable products
Dermovate · DIN 02213281 · $0.3996
Taro-Clobetasol Topical Solution USP · DIN 02245522 · $0.3996
Shortage status: resolved shortage (ended March 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02216213
Shortage record checked October 6, 2026
Taro-Clobetasol Topical Solution USP · DIN 02245522 · 0.05% · Scalp Lot
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Clobetasol Topical Solution USP · DIN 02245522
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2003-01-30
Health Canada: Marketed since 2005-10-03 · brand TARO-CLOBETASOL TOPICAL SOLUTION USP, 0.05% · ATC D07AD01 CLOBETASOL · form Solution · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Taro pharmaceuticals inc · schedule Prescription
Taro-Clobetasol Topical Solution USP: Formulary list price $0.40 per unit (the source does not state the unit; exact figure $0.3996). What the ministry pays, not the patient.
DIN 02245522: Taro-Clobetasol Topical Solution USP
Raw flags: sec3=Y
Item: 840600070; group id 841; item number 2048; lccId None; manufacturer id TAR
Source form: Scalp Lot; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.3996; ministry $0.3996
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245522
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69609Interchangeable products
Dermovate · DIN 02213281 · $0.3996
Mylan-Clobetasol Scalp Application · DIN 02216213 · $0.3996
Shortage status: resolved shortage (ended July 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245522
Shortage record checked October 6, 2026
Clobex Shampoo · DIN 02256371 · 0.05% w/w · Top Shampoo
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Clobex Shampoo · DIN 02256371
Manufacturer: Galderma Canada Inc; listing date 2020-12-18
Health Canada: Marketed since 2004-12-15 · brand CLOBEX SHAMPOO · ATC D07AD01 CLOBETASOL · form Shampoo · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Galderma canada inc. · schedule Prescription
Clobex Shampoo: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02256371: Clobex Shampoo
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840600155; group id 841; item number 2049; lccId None; manufacturer id GAC
Source form: Top Shampoo; strength: 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02256371
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74161Interchangeable products
Reddy-Clobetasol Shampoo · DIN 02519437 · not recorded
Taro-Clobetasol Shampoo · DIN 02506203 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02256371
Shortage record checked October 6, 2026
Reddy-Clobetasol Shampoo · DIN 02519437 · 0.05% w/w · Top Shampoo
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Reddy-Clobetasol Shampoo · DIN 02519437
Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2021-11-30
Health Canada: Marketed since 2022-01-10 · brand REDDY-CLOBETASOL SHAMPOO · ATC D07AD01 CLOBETASOL · form Shampoo · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 % · company Dr. reddy's laboratories canada inc. · schedule Prescription
DIN 02519437: Reddy-Clobetasol Shampoo
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840600155; group id 841; item number 2049; lccId None; manufacturer id DRR
Source form: Top Shampoo; strength: 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0838; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519437
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100870Interchangeable products
Clobex Shampoo · DIN 02256371 · not recorded
Taro-Clobetasol Shampoo · DIN 02506203 · not recorded
Shortage status: resolved shortage (ended November 10, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519437
Shortage record checked October 6, 2026
Taro-Clobetasol Shampoo · DIN 02506203 · 0.05% w/w · Top Shampoo
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Taro-Clobetasol Shampoo · DIN 02506203
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2020-12-18
Health Canada: Marketed since 2020-12-22 · brand TARO-CLOBETASOL SHAMPOO · ATC D07AD01 CLOBETASOL · form Shampoo · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
DIN 02506203: Taro-Clobetasol Shampoo
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840600155; group id 841; item number 2049; lccId None; manufacturer id TAR
Source form: Top Shampoo; strength: 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0838; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02506203
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99554Interchangeable products
Clobex Shampoo · DIN 02256371 · not recorded
Reddy-Clobetasol Shampoo · DIN 02519437 · not recorded
Shortage status: resolved shortage (ended March 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02506203
Shortage record checked October 6, 2026
Clobex Spray · DIN 02299739 · 0.05% w/w · Top Sol Sp
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Clobex Spray · DIN 02299739
Manufacturer: Galderma Canada Inc; listing date 2018-09-27
Health Canada: Marketed since 2007-12-19 · brand CLOBEX SPRAY · ATC D07AD01 CLOBETASOL · form Spray · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 %/W/W · company Galderma canada inc. · schedule Prescription
Clobex Spray: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02299739: Clobex Spray
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840600153; group id 841; item number 2050; lccId None; manufacturer id GAC
Source form: Top Sol Sp; strength: 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02299739
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78510Interchangeable products
Apo-Clobetasol Spray · DIN 02475162 · not recorded
Jamp Clobetasol Spray · DIN 02534665 · not recorded
Odan Clobetasol · DIN 02490706 · not recorded
Sandoz Clobetasol · DIN 02495023 · not recorded
Taro-Clobetasol Spray · DIN 02489619 · not recorded
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02299739
Shortage record checked October 6, 2026
Jamp Clobetasol Spray · DIN 02534665 · 0.05% w/w · Top Sol Sp
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Clobetasol Spray · DIN 02534665
Manufacturer: Jamp Pharma Corporation; listing date 2024-01-31
Health Canada: Marketed since 2024-03-28 · brand JAMP CLOBETASOL SPRAY · ATC D07AD01 CLOBETASOL · form Spray · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 %/W/W · company Jamp pharma corporation · schedule Prescription
DIN 02534665: Jamp Clobetasol Spray
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840600153; group id 841; item number 2050; lccId None; manufacturer id JPC
Source form: Top Sol Sp; strength: 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.9259; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02534665
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102357Interchangeable products
Apo-Clobetasol Spray · DIN 02475162 · not recorded
Clobex Spray · DIN 02299739 · not recorded
Odan Clobetasol · DIN 02490706 · not recorded
Sandoz Clobetasol · DIN 02495023 · not recorded
Taro-Clobetasol Spray · DIN 02489619 · not recorded
Shortage status: active shortage (reported September 15, 2026, estimated to end February 26, 2027, last updated September 23, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534665
Shortage record checked October 6, 2026
Odan Clobetasol · DIN 02490706 · 0.05% w/w · Top Sol Sp
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Odan Clobetasol · DIN 02490706
Manufacturer: Odan Laboratories Ltd.; listing date 2019-11-29
Health Canada: Marketed since 2019-09-26 · brand ODAN CLOBETASOL SPRAY · ATC D07AD01 CLOBETASOL · form Spray · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 %/W/W · company Odan laboratoriesltd · schedule Prescription
DIN 02490706: Odan Clobetasol
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840600153; group id 841; item number 2050; lccId None; manufacturer id ODN
Source form: Top Sol Sp; strength: 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.9260; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02490706
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98076Interchangeable products
Apo-Clobetasol Spray · DIN 02475162 · not recorded
Clobex Spray · DIN 02299739 · not recorded
Jamp Clobetasol Spray · DIN 02534665 · not recorded
Sandoz Clobetasol · DIN 02495023 · not recorded
Taro-Clobetasol Spray · DIN 02489619 · not recorded
Shortage status: resolved shortage (ended February 9, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02490706
Shortage record checked October 6, 2026
Taro-Clobetasol Spray · DIN 02489619 · 0.05% w/w · Top Sol Sp
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Clobetasol Spray · DIN 02489619
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2019-11-29
Health Canada: Marketed since 2019-08-26 · brand TARO-CLOBETASOL SPRAY · ATC D07AD01 CLOBETASOL · form Spray · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
DIN 02489619: Taro-Clobetasol Spray
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840600153; group id 841; item number 2050; lccId None; manufacturer id TAR
Source form: Top Sol Sp; strength: 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.9259; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02489619
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97970Interchangeable products
Apo-Clobetasol Spray · DIN 02475162 · not recorded
Clobex Spray · DIN 02299739 · not recorded
Jamp Clobetasol Spray · DIN 02534665 · not recorded
Odan Clobetasol · DIN 02490706 · not recorded
Sandoz Clobetasol · DIN 02495023 · not recorded
Shortage status: active shortage (reported January 20, 2026, estimated to end November 6, 2026, last updated September 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02489619
Shortage record checked October 6, 2026
Apo-Clobetasol Spray · DIN 02475162 · 0.05% w/w · Top Sol Sp
Off-Formulary Interchangeable, not an ODB benefitDormant since June 13, 2021 · checked October 5, 2026 · What does dormant mean?
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Clobetasol Spray · DIN 02475162
Manufacturer: Apotex Inc.; listing date 2018-09-27
Health Canada: Dormant since 2021-06-13 · brand APO-CLOBETASOL SPRAY · ATC D07AD01 CLOBETASOL · form Spray · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 %/W/W · company Apotex inc · schedule Prescription
DIN 02475162: Apo-Clobetasol Spray
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840600153; group id 841; item number 2050; lccId None; manufacturer id APX
Source form: Top Sol Sp; strength: 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.9259; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02475162
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96546Interchangeable products
Clobex Spray · DIN 02299739 · not recorded
Jamp Clobetasol Spray · DIN 02534665 · not recorded
Odan Clobetasol · DIN 02490706 · not recorded
Sandoz Clobetasol · DIN 02495023 · not recorded
Taro-Clobetasol Spray · DIN 02489619 · not recorded
Shortage status: discontinued (September 1, 2022, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475162
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since June 13, 2021 — choose a marketed DIN from the same-category list.
Sandoz Clobetasol · DIN 02495023 · 0.05% w/w · Top Sol Sp
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-08-31 — choose a marketed DIN from the same-category list.Discontinued August 31, 2026 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-08-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2026-08-31 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Clobetasol · DIN 02495023
Manufacturer: Sandoz Canada Inc.; listing date 2020-07-31
Health Canada: Cancelled post market since 2026-08-31 · brand SANDOZ CLOBETASOL · ATC D07AD01 CLOBETASOL · form Spray · route Topical · ingredients CLOBETASOL PROPIONATE 0.05 %/W/W · company Sandoz canada incorporated · schedule Prescription
DIN 02495023: Sandoz Clobetasol
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840600153; group id 841; item number 2050; lccId None; manufacturer id SDZ
Source form: Top Sol Sp; strength: 0.05% w/w
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.9259; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02495023
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98498Interchangeable products
Apo-Clobetasol Spray · DIN 02475162 · not recorded
Clobex Spray · DIN 02299739 · not recorded
Jamp Clobetasol Spray · DIN 02534665 · not recorded
Odan Clobetasol · DIN 02490706 · not recorded
Taro-Clobetasol Spray · DIN 02489619 · not recorded
Shortage status: discontinued (July 2, 2025, reported by SANDOZ CANADA INCORPORATED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02495023
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 31, 2026 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (D07A): coverage varies; not interchangeable
Amcinonide (Cyclocort): general benefit, not a benefit
Beclomethasone dipropionate (Propaderm): general benefit
Betamethasone dipropionate (Diprosone): general benefit
Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
Betamethasone valerate (Betnovate-1/2): general benefit, not a benefit
8 more in the class list below
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered
Matched class: 84:06 Anti-Inflammatory
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE
Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE
84:06 Anti-Inflammatory
· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.2% · Cr, Oint
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:06
and 5 more
INDICATIONS AND CLINICAL USE
TEVA-CLOBETASOL (clobetasol 17-propionate 0.05%): Cream and Ointment: For
the topical therapy of recalcitrant corticosteroid-responsive dermatoses, including
severe cases of psoriasis (excluding widespread plaque psoriasis) and eczematous
dermatitis.
Scalp lotion: Application is indicated for the topical treatment of recalcitrant
corticosteroid-responsive dermatoses of the scalp, including recalcitrant cases of
psoriasis and seborrheic dermatitis.
https://pdf.hres.ca/dpd_pm/00042697.PDF
PM date: not printed or not captured
Source product: TEVA-CLOBETASOL; DIN 01910272; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Taro-Clobetasol Cream USP · DIN 02245523
Shortage status: discontinued (2026-05-19, reported by TARO PHARMACEUTICALS INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245523
Clobex Spray · DIN 02299739
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02299739
Jamp Clobetasol Spray · DIN 02534665
Shortage status: active shortage (reported 2026-09-15, estimated to end 2027-02-26, last updated 2026-09-23); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534665
Taro-Clobetasol Spray · DIN 02489619
Shortage status: active shortage (reported 2026-01-20, estimated to end 2026-11-06, last updated 2026-09-18); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02489619
Apo-Clobetasol Spray · DIN 02475162
Shortage status: discontinued (2022-09-01, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475162
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules):
ODB 65 and over (seniors path)
Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗)
Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗)
Eligibility: Individual annual net income threshold
Program year August 1, 2026 to July 31, 2027: $25,480
This applies to a senior who:
does not have a spouse
has a married spouse with whom they no longer live in a conjugal relationship
has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗)
Eligibility: Combined annual net income requirement
Program year August 1, 2026 to July 31, 2027: $42,290
This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗)
Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗)
What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗)
Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗)
Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100.
That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year).
For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25.
Use this chart below to see what the deductible will be in your first year:
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Other review policies
For Clobex Shampoo, Reddy-Clobetasol Shampoo, Taro-Clobetasol Shampoo, Clobex Spray, Jamp Clobetasol Spray, Odan Clobetasol, Taro-Clobetasol Spray, Apo-Clobetasol Spray, Sandoz Clobetasol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.